Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China flag China · Delayed Price · Currency is CNY
18.01
-0.18 (-0.99%)
Oct 27, 2026, 4:00 PM EDT

SHE:301263 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Operating Revenue
680.87674.02720.17760.07782.8653.65
Other Revenue
0.880.880.860.720.68-
681.75674.9721.03760.79783.48653.65
Revenue Growth
1.08%-6.40%-5.23%-2.90%19.86%-7.80%
Cost of Revenue
306.15317.6319.09303.93328.67326.37
Gross Profit
375.61357.3401.94456.85454.81327.28
Selling, General & Admin
307.87269.3203.97202.59211.83163.4
Research & Development
68.5277.6886.4262.8940.3926.46
Other Operating Expenses
5.612.421.733.784.357.08
Operating Expenses
380.42351.46291.88273.14260.03199.77
Operating Income
-4.815.84110.06183.71194.78127.5
Interest Expense
-5.13-12.63-8.63-1.7-2.58-4.72
Interest & Investment Income
5.953.949.5116.4819.130.87
Currency Exchange Gain (Loss)
-0.57-0.57-2.3-0.88-4.340.53
Other Non Operating Income (Expenses)
-10.73-0.34-0.16-0.12-0.11-0.25
EBT Excluding Unusual Items
-15.3-3.76108.48197.49206.88123.93
Gain (Loss) on Sale of Investments
0.240.20.10.80.65-
Gain (Loss) on Sale of Assets
1.790.19-0.150.01-0.02
Asset Writedown
-2.63-0.9-1.27-7.61-0.3-0.5
Other Unusual Items
-2.47-3.9-1.741.50.1214.14
Pretax Income
-18.37-8.17105.57192.32207.35137.54
Income Tax Expense
-29.08-20.928.5338.8232.7517.55
Earnings From Continuing Operations
10.7212.7597.04153.5174.6120
Minority Interest in Earnings
1815.8911.186.70.010.07
Net Income
28.7128.63108.22160.2174.61120.07
Net Income to Common
28.7128.63108.22160.2174.61120.07
Net Income Growth
23.28%-73.54%-32.45%-8.25%45.43%-25.34%
Shares Outstanding (Basic)
472491499506476381
Shares Outstanding (Diluted)
472491499506476381
Shares Change
-9.79%-1.66%-1.27%6.23%24.85%6.51%
EPS (Basic)
0.060.060.220.320.370.31
EPS (Diluted)
0.060.060.220.320.370.31
EPS Growth
36.67%-73.10%-31.58%-13.63%16.49%-29.90%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Free Cash Flow
-15.7-121.1620.78-106.4858.9475.38
Free Cash Flow Per Share
-0.03-0.250.04-0.210.120.20
Dividend Per Share
0.0420.0420.1670.2500.3240.162
Dividend Growth
-74.98%-74.98%-33.32%-22.86%100.06%-
Gross Margin
55.09%52.94%55.74%60.05%58.05%50.07%
Operating Margin
-0.71%0.86%15.26%24.15%24.86%19.51%
Profit Margin
4.21%4.24%15.01%21.06%22.29%18.37%
Free Cash Flow Margin
-2.30%-17.95%2.88%-14.00%7.52%11.53%
EBITDA
67.1369.59162.89221.01226.75155.09
EBITDA Margin
9.85%10.31%22.59%29.05%28.94%23.73%
D&A For EBITDA
71.9463.7552.8337.331.9727.58
EBIT
-4.815.84110.06183.71194.78127.5
EBIT Margin
-0.71%0.86%15.26%24.15%24.86%19.51%
Effective Tax Rate
--8.08%20.19%15.79%12.76%
Revenue as Reported
149.07674.9721.03760.79783.48653.65
Advertising Expenses
-109.3865.8671.6995.6961.51